Analystreport

Castle Biosciences (NASDAQ: CSTL) had its price target raised by analysts at Canaccord Genuity from $41.00 to $47.00. They now have a "buy" rating on the stock.

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report